The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Associations between age at diagnosis and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer. Patients who received NACT and UBS and associated delays by sub-cohort (n = ...

Bin Yu; Jin Zhou; Hongzhou Cai; Ting Xu; Zicheng Xu; Qing Zou; Min Gu ...

evaluated neoadjuvant nivolumab plus chemotherapy. The study demonstrated statistically significant and clinically meaningful improvements in event-free survival and pathological complete response ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b ...

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

The role of income level in outcomes and treatment for patients with fibrolamellar hepatocellular carcinoma.

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...